TY - JOUR T1 - Efficacy of cidofovir versus bevacizumab in recurrent respiratory papillomatosis: A randomized, double-blind, placebo-controlled pilot study JO - Acta Otorrinolaringológica Española T2 - AU - Ablanedo-Terrazas,Yuria AU - Estrada-Camacho,Oscar AU - Alvarado-de la Barrera,Claudia AU - Ramírez-García,Arturo AU - Tona-Acedo,Gabriel AU - Bross-Soriano,Daniel AU - Schimelmitz-Idi,José SN - 21735735 M3 - 10.1016/j.otoeng.2020.12.001 DO - 10.1016/j.otoeng.2020.12.001 UR - https://www.elsevier.es/en-revista-acta-otorrinolaringologica-espanola-402-articulo-efficacy-cidofovir-versus-bevacizumab-in-S2173573522000308 AB - ObjectivesAfter surgical resection of papilloma, adjuvant therapy may be recommended for the control of recurrent respiratory papillomatosis (RRP). As the efficacy of adjuvant therapy remains unproven, the aim of this study was to compare the efficacy of cidofovir versus bevacizumab used as adjuvant therapies for the control of RRP. MethodsThis randomized, double-blind, placebo-controlled pilot study was performed in a national respiratory disease referral centre. Patients with RRP were recruited prospectively and were divided into juvenile or adult RRP. Participants were randomly assigned to receive adjuvant therapy with cidofovir, bevacizumab or placebo. The study drug or placebo was administered after direct microlaryngoscopy with papilloma resection using cold instruments. The Derkay severity score and the Voice Handicap Index (VHI) were assessed at 3–6-week intervals, for a total of 3 visits. Follow-up included VHI and Derkay score assessments at 2-month intervals over the course of one year. Annual rates before and after surgical treatment were compared. ResultsFive children and 11 adults were enrolled in the study. After one year, the group treated with cidofovir had a significant decrease in Derkay score (p=.027). No difference between treatment arms was observed in the annual surgery rate. There was a significant decrease in the VHI score in all treatment groups (p<.001), and no significant difference was observed between groups (p=.32). ConclusionWhile we observed a significant decrease in RRP severity with intralesional cidofovir, we were unable to provide proof of efficacy of intralesional bevacizumab.Clinicaltrials.gov Identifier: NCT02555800. ER -